ESMO 2024: Treatment of uHCC - Episode 1

Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)

, , , , ,

Panelists discuss the current landscape of first-line treatment for unresectable hepatocellular carcinoma, highlighting key options and decision-making factors.

Now Viewing
EP. 1: Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)
EP. 2: Treatment Decisions Based on BLCL Stage
EP. 3: Current Treatment in First Line – IO + TKI or IO + IO
EP. 4: Use of monotherapy (IO or TKI) or localized treatment in First Line
EP. 5: EMERALD-1 Study Results
EP. 6: Discussion and Summary
EP. 7: LEAP-012 Study Results
EP. 8: Discussion of LEAP-012 and EMERALD-1 Study Results and Appropriate Sequencing
EP. 9: ImBRAVE 050 Study Results and Discussion Around Who is a High-Risk Patient
EP. 10: Choosing Second-Line Therapies: Considering First Line Therapy Received
EP. 11: Discussion of CELESTIAL Trial and Second-Line Treatment in Japan
EP. 12: CELESTIAL Sub-Group Discussion
EP. 13: Discussion of RESORCE Trial
EP. 14: Real-World Treatment Data from the Phase 4 STELLAR Trial
EP. 15: Importance of Real-World Data in Supporting Treatment Options
EP. 16: CheckMate 9DW Study Results and Use of Ipiimumab/Nivolumab in First- and Second-Line Treatment
EP. 17: Future Directions for Treating uHCC: Triplet Therapy, Epigenetic Therapy, Cytotoxic Agents, and Antibody-Drug Conjugates (ADCs

Video content above is prompted by the following:

Briefly explore the current landscape of first-line treatment for unresectable hepatocellular carcinoma

Related Content:

ESMO 2024: Treatment of uHCC
Future Directions for Treating uHCC: Triplet Therapy, Epigenetic Therapy, Cytotoxic Agents, and Antibody-Drug Conjugates (ADCs
CheckMate 9DW Study Results and Use of Ipiimumab/Nivolumab in First- and Second-Line Treatment
Importance of Real-World Data in Supporting Treatment Options